1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024

EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024

Summary

Systemic sclerosis (SSc) is an autoimmune disease of the connective tissue, and is characterized by excessive fibrosis, vascular alterations, and the proliferation of antibodies against numerous cellular antigens. SSc mainly affects those ages 40-50 years, and occurs predominantly in women, with a female-to-male sex ratio of 4:1. There are two main forms of the disease: limited and diffuse cutaneous scleroderma (lSSc and dSSc, respectively). lSSc primarily affects the hands, arms, and face, whereas dSSc affects a vast area of the skin and involves one or more internal organs. Raynaud’s phenomenon (RP) develops in the majority of both forms of SSc. The primary cause of death in both lSSC and dSSc is involvement of the lungs.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of SSc for ages 18 years and older will increase from 131,129 cases in 2014 to 141,499 cases in 2024. GlobalData epidemiologists forecast that in 2024, the US will have the highest number of diagnosed prevalent cases of SSc, with 95,992 cases, accounting for 68% of cases in the 7MM. In the 7MM in 2014, the group age 50-59 years had the highest proportion of diagnosed prevalent cases of SSc at 25.51%. In 2014, the diagnosed prevalent cases of SSc in the 7MM were lower in men compared with women with 15.36% diagnosed prevalent cases in men and 84.64% diagnosed prevalent cases in women. Of all the diagnosed prevalent cases of SSc in the 7MM in 2014, more had experienced RP (126,151 cases) than a DU (67,099 cases). In each of the 7MM, approximately 95% of the diagnosed prevalent SSc cases had experienced RP. In all markets other than France, Germany, and Italy, 70.50% of the diagnosed prevalent cases of SSc were lSSc. In the 7MM in 2014, 18,395 of the diagnosed prevalent cases of dSSc had ILD, and 6,679 of the diagnosed prevalent cases of dSSc had kidney disease.

GlobalData epidemiologists utilized comprehensive, country-specific data from registries and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of SSc. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for the diagnosed prevalent cases of SSc. Finally, the same forecast methodology was used across the 7MM, thereby allowing for meaningful global comparisons of the diagnosed prevalent cases of SSc across these markets.

Scope

- The Systemic Sclerosis (SSc) EpiCast Report provides an overview of the risk factors and global trends of SSc in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of SSc diagnosed prevalent cases in these markets, segmented by age, sex, presence of Raynaud’s phenomenon (RP), presence of digital ulcers (DUs), limited systemic sclerosis (ISSc), and diffuse systemic sclerosis (dSSc). The diagnosed prevalent cases of dSSc are further segmented into cases with pulmonary fibrosis (PF)/interstitial lung disease (ILD) and kidney disease.
- The SSc epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The SSc EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global SSc market.
- Quantify patient populations in the global SSc market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SSc therapeutics in each of the markets covered.
- Identify the percentage of SSc diagnosed prevalent cases by disease type.

Table Of Contents

EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 12
3.4 Forecast Methodology 14
3.4.1 Sources Used 15
3.4.2 Sources Not Used 30
3.4.3 Forecast Assumptions and Methods 30
3.5 Epidemiological Forecast for SSc (2014-2024) 43
3.5.1 Diagnosed Prevalent Cases of SSc 43
3.5.2 Age-Specific Diagnosed Prevalent Cases of SSc 44
3.5.3 Sex-Specific Diagnosed Prevalent Cases of SSc 47
3.5.4 Age-Standardized Prevalence of SSc 48
3.5.5 Diagnosed Prevalent Cases of SSc with RP and SSc with DU 49
3.5.6 SSc Segmented into lSSc and dSSc 51
3.5.7 Sex-Specific Diagnosed Prevalent Cases of lSSc 52
3.5.8 Sex-Specific Diagnosed Prevalent Cases of dSSc 53
3.5.9 Diagnosed Prevalent Cases of dSSc with ILD and Cases with Kidney Disease 54
3.6 Discussion 56
3.6.1 Epidemiological Forecast Insight 56
3.6.2 Limitations of the Analysis 56
3.6.3 Strengths of the Analysis 57
4 Appendix 58
4.1 Bibliography 58
4.2 About the Authors 63
4.2.1 Epidemiologists 63
4.2.2 Reviewers 64
4.2.3 Global Director of Therapy Analysis and Epidemiology 65
4.2.4 Global Head of Healthcare 65
4.3 About GlobalData 66
4.4 About EpiCast 66
4.5 Disclaimer 67

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for SSc 11
Table 2: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc 15
Table 3: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc with RP 16
Table 4: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc with DU 17
Table 5: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc, Segmented by lSSc and dSSc 18
Table 6: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of dSSc with ILD 19
Table 7: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of dSSc with Kidney Disease 20
Table 8: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, Age ?18 Years, Select Years, 2014-2024 43
Table 9: 7MM, Age-Specific Diagnosed Prevalent Cases of SSc, Both Sexes, N (Row%), 2014 45
Table 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of SSc, Age ?18 Years, N (Row %), 2014 47
Table 11: 7MM, Diagnosed Prevalent Cases of SSc with RP, and SSc with DU, Both Sexes, Age ?18 Years, N (% of Diagnosed Prevalent SSc Cases), 2014 50
Table 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of lSSc, Age ?18 Years, N (Row %), 2014 53
Table 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of dSSc, Ages ?18 Years, N (Row %), 2014 54
Table 14: 7MM, Diagnosed Prevalent Cases of dSSc with ILD and dSSc with Kidney Disease, Both Sexes, Age ?15 Years, N (% of Diagnosed Prevalent dSSc Cases), 2014 55

1.2 List of Figures
Figure 1: Case Flow Map of the Diagnosed Prevalent Cases of SSc 21
Figure 2: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, Age ?18 Years, Selected Years, 2014-2024 44
Figure 3: 7MM, Age-Specific Diagnosed Prevalent Cases of SSc, Both Sexes, 2014 46
Figure 4: 7MM, Sex-Specific Diagnosed Prevalent Cases of SSc, Age ?18 Years, 2014 48
Figure 5: 7MM, Age-Standardized Diagnosed Prevalence of SSc, 2014 49
Figure 6: 7MM, Diagnosed Prevalent Cases of SSc with RP and SSc with DU, Both Sexes, Age ?18 Years, N, 2014 51
Figure 7: 7MM, Diagnosed Prevalent Cases of SSc Classified as lSSc and dSSc, Both Sexes, Age ?18 Years, N, 2014 52

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Polycystic kidney disease (PKD)- Market Insights, Epidemiology and Market Forecast-2023

Polycystic kidney disease (PKD)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Polycystic kidney disease (PKD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Polycystic kidney disease (PKD) - Epidemiology Forecast To 2023

Polycystic kidney disease (PKD) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Polycystic kidney disease (PKD) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Polycystic kidney disease (PKD) in seven major markets (US, France, ...

Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H2, 2016

Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • September 2016
  • by Global Data

Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.